Navigation Links
VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
Date:9/17/2013

SARATOGA, Calif., Sept. 17, 2013 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc. ("VisionCare"), the developer, manufacturer and marketer of the Implantable Miniature Telescope ("IMT" by Dr. Isaac Lipshitz), the only FDA-approved surgical device for end-stage Age-Related Macular Degeneration ("AMD"), announced that it has secured up to $15 Million in long-term, non-dilutive financing to accelerate the commercialization of its novel therapy.  The capital was raised exclusively from Life Sciences Alternative Funding LLC ("LSAF"), a leading provider of non-dilutive, debt capital to fund growth for commercial-stage medical device and other life sciences companies.  

VisionCare's telescope implant was approved by the FDA in 2010 based on a multi-center, prospective clinical trial with more than five years of follow-up data.  VisionCare began to commercialize the first-of-kind device in 2011 via its CentraSight® treatment program and received a new CPT® code* for the implant from the American Medical Association (AMA) in July 2012.  In July 2013, Centers for Medicare and Medicaid Services (CMS) proposed to provide permanent reimbursement for the implant by assigning the telescope implant procedure to a new Ambulatory Payment Classification (APC).  If finalized, the new APC would be effective January 1, 2014.  The telescope will continue to be reimbursed by a transitional pass-through payment code, specifically created by CMS for the new technology in 2011, through January 1, 2014.

"This funding will help VisionCare drive continued adoption of this vision-improving procedure and provide life-changing therapy to end-stage AMD patients," said Allen Hill, CEO of VisionCare.  "Along with the recent
'/>"/>

SOURCE VisionCare Ophthalmic Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings
2. VisionCare Receives Health Canada License for First-Ever Telescope Prosthesis for End-Stage Macular Degeneration
3. CMS Proposes Permanent Medicare Payment for VisionCares Telescope Implant for Macular Degeneration
4. Ophthalmic Drugs: World Market Prospects 2012-2022
5. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
6. Innovations in Ophthalmic Devices - Anterior Segment
7. Ohr Pharmaceutical Announces Additions to Ophthalmic Scientific Advisory Board
8. Medical Device Market Updates: IVD and Ophthalmic Devices Dominate Chinas $30.5 bn Medical Device Market; Invisible Hearing Aids Set to Make Big Noise
9. India Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
10. Seeing Life Through Many Lenses: Different Ophthalmic Lenses for Different Lifestyles
11. United States Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
(Date:6/29/2015)... Van Nuys, CA (PRWEB) , ... June 29, ... ... release of its new YouTube video, “Lake Balboa Care Center”, showcasing its prestigious ... health inspections, staffing, and quality measures. Lake Balboa views this rating as indicative ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors and Usability Studies: ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors , The ... to the design of new products as well as to postmarket surveillance of ...
(Date:6/29/2015)... , ... June 29, 2015 , ... With Urgent Care ... a partnership with the American Board of Urgent Care Medicine and the Medical Society ... 1 Credit™ to Urgent Care physicians and health care professionals. , According to Matthew ...
(Date:6/29/2015)... VA (PRWEB) , ... June 29, 2015 , ... The ... from the Virginia Aviation Museum to the Science Museum of Virginia. This iconic, supersonic ... opening early 2016. , “Suspending a supersonic jet from the ceiling of a historic ...
(Date:6/29/2015)... ... , ... FACE is proud to be one of the first in the ... chin and redefining of the jawline. Excess fat under the chin and around ... the person distress and poor self-image. , Kybella was produced by KYTHRA Biopharmaceutical and ...
Breaking Medicine News(10 mins):Health News:Lake Balboa Releases New Facility Video of Patient Testimonials 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3Health News:SR-71 Prepares for Flight to Science Museum of Virginia 2Health News:FACE Detroit Skin and Wellness Clinic Introduces Newly FDA Approved Kybella for the elimination of the Double Chin. 2
... say the report from China is no cause for ... have identified a probable case of human-to-human transmission of ... to the idea that there,s a genetic component to ... study reported. , "This suggests that there,s some genetic ...
... Albemarle,Corporation (NYSE: ALB ) will hold its quarterly conference ... at 8:00am ET., This call is being webcast by ... http://www.albemarle.com in the Investor,Information section., ... Dial In # 800-591-6942 International ...
... NEW YORK, April 7, 2008 American Media, ... at its corporate website certain,information currently required to ... lenders under its amended Senior Secured Credit Agreement., ... monthly,circulation of certain key magazine titles during the ...
... 2008 DURECT,Corporation (Nasdaq: DRRX ) announced ... to return the rights to CHRONOGESIC(R) licensed from,DURECT ... a product,candidate consisting of a sufentanil containing implantable ... As a result, the,Development, Commercialization and Supply License ...
... University School of Medicine in St. Louis report that ... operative procedure they achieved a significant improvement in the ... , Reporting in the April issue of the Journal ... enhancement to the Cox-Maze procedure, a surgical procedure that ...
... to Help Provide Tetanus Vaccines to ... in Developing Countries, CINCINNATI, April 7, 2008 ... decades and today, the world,s leading,diaper brand kicked off ... to UNICEF to provide life-saving tetanus,vaccines to women of ...
Cached Medicine News:Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 2Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 3Health News:Albemarle Corporation's First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 8:00am ET 2Health News:DURECT Provides Update on CHRONOGESIC(R) Research Program 2Health News:Surgeons announce advance in atrial fibrillation surgery 2Health News:Surgeons announce advance in atrial fibrillation surgery 3Health News:Actress/Producer Salma Hayek Launches The Pampers(R) 'One Pack = One Vaccine' Program to Benefit UNICEF 2Health News:Actress/Producer Salma Hayek Launches The Pampers(R) 'One Pack = One Vaccine' Program to Benefit UNICEF 3Health News:Actress/Producer Salma Hayek Launches The Pampers(R) 'One Pack = One Vaccine' Program to Benefit UNICEF 4Health News:Actress/Producer Salma Hayek Launches The Pampers(R) 'One Pack = One Vaccine' Program to Benefit UNICEF 5
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: